Holen Sie sich die Stockscreener-App
5.28
2.22%
-0.12
Handel nachbörslich:
5.02
-0.26
-4.92%
Schlusskurs vom Vortag:
$5.40
Offen:
$5.3
24-Stunden-Volumen:
1.22M
Relative Volume:
0.63
Marktkapitalisierung:
$510.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-18.21
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
-15.11%
1M Leistung:
-13.01%
6M Leistung:
+76.00%
1J Leistung:
+93.41%
1-Tages-Spanne:
$4.85
$5.32
1-Wochen-Bereich:
$4.85
$6.15
52-Wochen-Spanne:
$2.30
$7.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
5.28 | 510.48M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.39 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
546.22 | 33.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
226.28 | 29.29B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
208.31 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLC - Defense World
Trevi Therapeutics at 24th Annual Needham: Strategic Advances in Cough Treatments - Investing.com Canada
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Bought by Bank of New York Mellon Corp - The AM Reporter
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock By Investing.com - Investing.com Australia
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey
Leerink Partnrs Analysts Boost Earnings Estimates for TRVI - Defense World
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst - Defense World
Equities Analysts Offer Predictions for TRVI Q2 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley - Defense World
D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at B. Riley - The AM Reporter
Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00 - Defense World
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $15.94 - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials - Markets Insider
Needham & Company LLC Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - The AM Reporter
B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating - Marketscreener.com
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... - Yahoo
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing Promising Trials - GuruFocus
Trevi Therapeutics Advances Haduvio in Clinical Trials - TipRanks
Earnings call transcript: Trevi Therapeutics Q4 2024 reports mixed results - Investing.com
Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates - PR Newswire
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study - MSN
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week - Yahoo Finance
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Analysts Increase Earnings Estimates for TRVI - Defense World
Stock Traders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - The AM Reporter
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock - Investing.com India
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High After Analyst Upgrade - Defense World
Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Wednesday - Defense World
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 - The Malaysian Reserve
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer - TipRanks
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Given New $12.50 Price Target at HC Wainwright - Defense World
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.35%
10.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):